CureVac (NASDAQ:CVAC) Shares Gap Down – Here’s What Happened

CureVac (NASDAQ:CVAC)’s stock price gapped down prior to trading on Friday . The stock had previously closed at $3.20, but opened at $3.13. CureVac shares last traded at $3.14, with a volume of 99,760 shares changing hands.

Analyst Upgrades and Downgrades

Separately, JMP Securities reaffirmed a “market outperform” rating and issued a $16.00 price target on shares of CureVac in a report on Friday, February 14th.

CureVac Price Performance

The company has a quick ratio of 6.19, a current ratio of 6.20 and a debt-to-equity ratio of 0.05. The business has a fifty day moving average of $3.66 and a 200 day moving average of $3.20. The firm has a market cap of $690.67 million, a P/E ratio of 5.59 and a beta of 2.53.

Institutional Trading of CureVac

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Barclays PLC bought a new stake in shares of CureVac in the third quarter valued at approximately $67,000. Public Employees Retirement System of Ohio acquired a new position in CureVac in the 3rd quarter valued at $91,000. Jane Street Group LLC lifted its position in shares of CureVac by 239.0% during the 3rd quarter. Jane Street Group LLC now owns 79,247 shares of the company’s stock valued at $235,000 after acquiring an additional 55,867 shares during the period. China Universal Asset Management Co. Ltd. grew its holdings in shares of CureVac by 10.3% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 47,568 shares of the company’s stock worth $162,000 after purchasing an additional 4,425 shares in the last quarter. Finally, International Assets Investment Management LLC bought a new position in shares of CureVac in the third quarter worth $35,000. Institutional investors and hedge funds own 17.26% of the company’s stock.

CureVac Company Profile

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.